ATMOS, a Proof-of-Concept trial of inhaled mosliciguat in untreated PAH or CTEPH
Hossein Ardeschir Ghofrani(Justus-Liebig-Universität Gießen), Grzegorz Kopeć(John Paul II Hospital), Tobias Lange(Universität Hamburg), Hikmet Al‐Hiti(Institute of Clinical and Experimental Medicine), Hanno Leuchte(Universität Hamburg), Johannes Nagelschmitz(University of Wuppertal), Michael Halank(University Hospital Carl Gustav Carus), Pavel Jansa(General University Hospital in Prague), Sylvia Nikkho(MerLion Pharma (Germany)), Sandra Ligges(University of Münster), Paula Vesterinen(Ferring Pharmaceuticals (Finland)), Horst Olschewski(Sigmund Freud Privatuniversität Wien), Khodr Tello(Universities of Giessen and Marburg Lung Center), Soundos Saleh(University of Wuppertal), Sudhir Penugonda(ClearMotion (United States)), David Jung(University of Wuppertal), Markus Woischnik(University of Wuppertal), Eva Becker‐Pelster(University of Wuppertal)
Cited by 2
Related Papers
2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension
|European Heart Journal|2022|3.6k
Inhaled Iloprost for Severe Pulmonary Hypertension
|New England Journal of Medicine|2002|1.8k
Riociguat for the Treatment of Chronic Thromboembolic Pulmonary Hypertension
|New England Journal of Medicine|2013|1.4k
Mechanisms of disease: pulmonary arterial hypertension
|Nature Reviews Cardiology|2011|784
Pulmonary hypertension in chronic lung disease and hypoxia
|European Respiratory Journal|2018|777